Shots:

• The P-III (FOCUS) trial evaluates fostamatinib (BID) + SoC vs PBO + SoC in 280 patients with COVID-19 without respiratory failure for 14 days with a follow-up period to Day 60
• The results showed the mean no. of days on oxygen through Day 29 (6.9 vs 9.0 days), a 50% reduction in patient all-cause mortality, mean change from baseline in clinical status score to Day 15 was -2.4 vs -1.9, the median no. of days to first sustained hospital discharge (6 vs 7 days), patients were alive and oxygen-free (85.1% vs 73.4%), no. of days in the ICU (2.2 vs 3.3)
• The safety profile was consistent with prior results with no new safety issues. All prespecified 2EPs were numerically favored fostamatinib

Ref: Rigel | Image: Rigel